

Approved for use through 05/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the
 tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PK TRADEMARK

Complete if Known

(Use as many sheets as necessary)

Sheet 1

of 11

| | |
|------------------------|-----------------|
| Application Number | 10/727,020 |
| Filing Date | 2 December 2003 |
| First Named Inventor | YONG, Eu Leong |
| Art Unit | 1654 |
| Examiner Name | |
| Attorney Docket Number | LLOYD1100 |

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ² |
| | | Country Code*-Number*-Kind Code* (if known) | | | | |
| SC | | EP 441278 A | 08-14-1991 | INDENA S.p.A. | . | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

**Examiner
Signature**

Arman D. Lee



Date _____

Considered 3-1-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/727,020 |
| Filing Date | 2 December 2003 |
| First Named Inventor | YONG, Eu Leong |
| Art Unit | 1654 |
| Examiner Name | |
| Attorney Docket Number | LLOYD1100 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|---|----------------|
| is | | MA X et al., "Preparative isolation and purification of calycosin from Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao by high-speed counter current chromatography", J. Chromatography A, 2002, 962: 243-247. | |
| is | | MA X et al., "Preparative isolation and purification of two isoflavones from Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao by high-speed counter current chromatography", J. Chromatography A, 2003, 992: 193-197. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |


| | | | |
|-----------------------|----------------------|--------------------|--------|
| Examiner Signature | <i>Morgan D. Lee</i> | Date Considered | 3-7-06 |
|-----------------------|----------------------|--------------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/727,020 |
| Filing Date | 2 December 2003 |
| First Named Inventor | YONG, Eu Leong |
| Art Unit | 1654 |
| Examiner Name | Unassigned |
| Attorney Docket Number | LLOYD1100 |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| gl | A | ATKINSON et al. "Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial" Breast Cancer Research, Vol 6 No. 3, 2003 | |
| gl | B | LINSEISEN et al. "Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study" Int. J. Cancer 110, 284-290, 2004 | |
| gl | C | JARRED et al. "Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones" Vol 11, 1689-1696, 2002 | |
| gl | D | Pharmacopoeia of the People's Republic of China, "Radix astragali" Chemical Industry Press, Beijing, China, Vol. 1, 142, 1997 | |
| gl | E | QIAN et al. "Viral etiology of chronic cervicitis and its therapeutic response to a recombinant interferon" Chinese Medical Journal, 103(8): 647-651, 1990 | |
| gl | F | SUN A. and CHIANG C.P "Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus" J Oral Pathol Med 30: 542-8, 2001 | |
| gl | G | LU et al. "Preventive effect of radix astragali on insulin resistance caused by tumor necrosis factor-alpha, Zhongguo Zhong Xi Yi Jie He Za Zhi, 19(7): 420-2, 1999 (text in Chinese) | |
| gl | H | MA et al. "Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure" Chinese Medical Journal, 111(1): 17-23, 1998 | |
| gl | I | YANG et al. "Treatment of experimental coxsackie B-3 viral myocarditis with astragalus membranaceus in mice" Chinese Medical Journal, 103(1): 14-18, 1990 | |
| gl | J | MA et al. "Preparative isolation and purification of two isoflavones from astragalus membranaceus Bge. var. mongholicus (Bge) Hsiao by high-speed counter-current chromatograph" Journal of Chromatograph A, 992: 193-197, 2003 | |

| | | | |
|--------------------|-------------------|-----------------|--------|
| Examiner Signature | <i>Andrew Lee</i> | Date Considered | 3-7-06 |
|--------------------|-------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/727,020 |
| Filing Date | 2 December 2003 |
| First Named Inventor | YONG, Eu Leong |
| Art Unit | 1654 |
| Examiner Name | Unassigned |
| Attorney Docket Number | LLOYD1100 |

| | | | |
|-------|---|----|---|
| Sheet | 2 | of | 2 |
|-------|---|----|---|

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| gl | K | KAJIMURA et al. "Polysaccharide of astragali radix enhances lgm antibody production in aged mice" Biol. Pharm Bull, Vol 20, No. 11: 1178-1182, 1997 | |
| gl | L | ZHANG et al. "Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression" J Vasc Res, 34: 273-280, 1997 | |
| gl | M | SHIRATAKI et al. "Antioxidative components isolated from the roots of astragalus membranaceus bunge (astragali radix)" Phytotherapy Research, Vol. 11, 603-605, 1997 | |
| gl | N | Shizuo TODA and Yoshiaki SHIRATAKI "Inhibitory effects of isoflavones in roots of astragalus membranaceus bunge (astragali radix) on lipid peroxidation by reactive oxygen species" Phytotherapy Research, Vol 12, 59-61, 1998 | |
| gl | O | EISOHLY et al. "Antigiardial isoflavones from machaerium aristulatum" Planta Medica 65, 490, 1999 | |
| gl | P | KRAFT et al. "Antiplasmodial activity of isoflavones from andira inermis" Journal of Ethnopharmacology, 73: 131-135, 2000 | |
| gl | Q | Richard J. MIKSICEK "Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor" J. Steroid Biochem. Molec. Biol., Vol 49 No. 2/3, 153-160, 1994 | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|---------------------|-----------------|--------|
| Examiner Signature | <i>Brian D. Lee</i> | Date Considered | 3-7-06 |
|--------------------|---------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.